Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA |
| |
| Authors: | A A Al-Nahhas R A Jafri K E Britton K Solanki J Bomanji S Mather M A Carroll M Al-Janabi V Frusciante B Ajdinowic |
| |
| Affiliation: | Department of Nuclear Medicine, St. Bartholomew's Hospital, London, UK. |
| |
| Abstract: | The preparation, application and clinical usage of 99mTc-mercaptoacetyltriglycine, MAG3, a tubular secreted compound, is described in the first 225 patients in a phase III study. Image quality, relative renal function, and renal transit times were compared with a 4 fold greater administered activity of 99mTc-DTPA in 11 patients. Correlation coefficients of 0.94 for relative function, 0.83 for parenchymal transit time index and 0.82 for whole kidney transit time index were found. Frusemide responses were similar. 99mTc-MAG3 is an efficacious radiopharmaceutical for routine renal radionuclide studies, giving excellent image quality in patients with hypertension, poor renal function, obstructive nephropathy or a renal transplant. |
| |
| Keywords: | |
|
|
